接受雄激素剥夺治疗的前列腺癌患者闭孔内肌MRI评估:与体成分的关系及预后意义
回顾性研究纳入104例接受ADT的前列腺癌患者与84例良性前列腺增生对照,用MRI测量闭孔内肌横截面积和肌间脂肪组织,并与CT体成分对照。ADT组闭孔内肌面积和指数显著降低、肌间脂肪显著增加,OI-IMAT升高与更短的无进展生存期相关(p=0.039)。
要点
- ADT治疗前列腺癌患者随访MRI可见闭孔内肌面积降低、肌间脂肪增加(均p<0.001)。
- MRI测得的闭孔内肌丢失与CT骨骼肌丢失相关(r=0.530),肌间脂肪增加亦相关(r=0.515)。
- OI-IMAT升高与更短无进展生存期相关(p=0.039),可能提示治疗相关肌少症高风险。
核心结论
- ADT治疗前列腺癌患者闭孔内肌肌间脂肪增加幅度越大,无进展生存期越短;常规MRI评估闭孔内肌可能作为全身骨骼肌退化的间接标志。
研究设计与样本
- 回顾性研究,比较104例接受ADT的前列腺癌患者与84例良性前列腺增生对照,基线与随访前列腺MRI及胸腹部CT在2年间隔内完成,用Kaplan-Meier法分析无进展生存期。
关键影像表现/征象
- ADT组基线与随访间闭孔内肌面积、闭孔内肌指数显著降低,闭孔内肌肌间脂肪组织及指数显著增加(均p<0.001)。
- 84例对照组上述指标无变化(均p>0.05)。
- 45例有配对CT的前列腺癌患者中,骨骼肌、骨骼肌指数显著降低,骨骼肌肌间脂肪组织及指数显著增加(均p<0.001)。
诊断标准与关键数值
- MRI测量闭孔内肌横截面积与闭孔内肌肌间脂肪组织,CT测量腹部骨骼肌与骨骼肌肌间脂肪组织。
- CT骨骼肌丢失与MRI闭孔内肌丢失相关(r=0.530,p<0.001),CT骨骼肌肌间脂肪增加与MRI闭孔内肌肌间脂肪增加相关(r=0.515,p<0.001)。
- 闭孔内肌肌间脂肪组织升高与无进展生存期缩短相关(p=0.039)。
临床应用与阅片要点
- 常规前列腺MRI可机会性评估闭孔内肌萎缩和脂肪浸润,作为全身骨骼肌退化的间接标志。
- 监测闭孔内肌变化可能有助于识别ADT治疗前列腺癌患者中肌肉退化风险较高者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether routine prostate MRI can quantify atrophy and fatty infiltration of the obturator internus (OI) muscle in prostate cancer (PCa) patients undergoing androgen deprivation therapy (ADT), to explore concordance between MRI-derived OI metrics and CT-based body composition, and evaluate their impact on progression-free survival (PFS).
MATERIALS AND METHODS: In this retrospective study, ADT-treated PCa patients were compared with benign prostatic hyperplasia controls. Baseline and follow-up prostate MRI and chest/abdominal CT scans were performed within a 2-year interval. The cross-sectional area (CSA) of the OI and inter-muscular adipose tissue of obturator internus muscle (OI-IMAT) was measured using MRI. Abdominal skeletal muscle (SM) and inter-muscular adipose tissue (SM-IMAT) were assessed via CT. PFS was analyzed using Kaplan-Meier methods.
RESULTS: Among 104 ADT-treated PCa patients, significant reductions in OI area, OI index (OII) and increases in OI-IMAT, OI-IMAT index (OI-IMATI) were observed between baseline and follow-up (all p < 0.001). No changes were found in the 84 controls (all p > 0.05). In 45 PCa patients with paired CT, significant decreases in SM, SM index (SMI) and increases in SM-IMAT, IMAT index (SM-IMATI) were observed between baseline and follow-up (all p < 0.001). Loss of SM (CT) correlated with loss of OI (MRI) (r = 0.530, p < 0.001), and an increase in SM-IMAT (CT) correlated with OI-IMAT (MRI) (r = 0.515, p < 0.001). Furthermore, elevated OI-IMAT levels were found to adversely affect PFS (p = 0.039).
CONCLUSION: A greater increase in OI-IMAT was linked to shorter PFS in ADT-treated PCa patients. Routine MRI-based OI assessment may serve as an indirect marker of global skeletal muscle deterioration and help flag patients at heightened risk of treatment-related sarcopenia.
KEY POINTS: Question Routine prostate MRI can quantify obturator internus atrophy and fatty infiltration in PCa undergoing androgen deprivation therapy (ADT) to identify individuals at higher risk of muscle deterioration. Findings MRI-detected obturator internus (OI) changes mirror CT muscle loss/fat gain, indicating sarcopenia. An inter-muscular adipose tissue of obturator internus muscle (OI-IMAT) increase > 10% independently predicts shorter progression-free survival. Clinical relevance Prostate MRI may provide an opportunity for opportunistic assessment of OI muscle atrophy and fatty infiltration. Monitoring changes in the OI may offer a cost-effective way to identify individuals at higher risk of muscle deterioration in PCa patients undergoing ADT.
引用
- Yan J, Jiang N, Wu S, et al. MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT. Eur Radiol. 2025. PMID: 41307662. doi:10.1007/s00330-025-12156-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。